Acute therapy with intravenous omeprazole on caustic esophageal injury: a prospective case series

SUMMARY The ingestion of caustic substances may result in significant esophageal injury. There is no standard treatment protochol for esophageal injury and most patients are treated with a proton pump inhibitor or H2 antagonist. However, there is no clinical study evaluating the efficacy of omeprazo...

Full description

Saved in:
Bibliographic Details
Published in:Diseases of the esophagus Vol. 26; no. 1; pp. 22 - 26
Main Authors: Çakal, B., Akbal, E., Köklü, S., Babalı, A., Koçak, E., Taş, A.
Format: Journal Article
Language:English
Published: Malden, USA Blackwell Publishing Inc 01-01-2013
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SUMMARY The ingestion of caustic substances may result in significant esophageal injury. There is no standard treatment protochol for esophageal injury and most patients are treated with a proton pump inhibitor or H2 antagonist. However, there is no clinical study evaluating the efficacy of omeprazole for caustic esophageal injury. A prospective study of 13 adult patients (>18 years of age) who were admitted to our hospital for caustic ingestion between May 2010 and June 2010 was conducted. Mucosal damage was graded using a modified endoscopic classification described by Zargar et al. Patients were treated with a proton pump inhibitor and maintained without oral intake until their condition was considered stable. Patients received omeprazole 80 mg in bolus IV, followed by continuous infusion of 8 mg/hour for 72 hours. A control endoscopy was performed 72 hours after admission. There was significant difference regarding endoscopic healing between the before and after omeprazole infusion (P = 0.004). There was no hospital mortality at the follow‐up. Omeprazole may effectively be used in the acute phase treatment of caustic esophagus injuries.
Bibliography:istex:2CCE722B0E46D0E73855E3E0E058D8B97ACDC40A
ArticleID:DOTE1319
ark:/67375/WNG-7J7428TV-3
Acknowledgments, sources of funding, conflict of interest statements, and all author (Başak Çakal, Erdem Akbal, Seyfettin Köklü, Ayşegül Babalı, Erdem Koçak, Adnan Taş) disclosures: No commercial party having a direct financial support, any conflict of interest (funding source, or commercial interest including pharmaceutical or device companies) in the results of the research supporting this article has or will confer a benefit to the authors or to any organization with which the authors are associated. Başak Çakal, Erdem Akbal, Seyfettin Köklü, Ayşegül Babalı, Erdem Koçak, and Adnan Taş have no conflicts of interest or financial ties to disclose.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1120-8694
1442-2050
DOI:10.1111/j.1442-2050.2011.01319.x